A previous study determined that the use of the Bac CPP to target the ELP-delivered c-Myc inhibitory peptide (Bac-ELP-H1) to the nucleus was more potent than the use of cytoplasmically targeted CPPs in breast cancer cell lines [30]. The gene discussed is NR5A1; the disease is breast carcinoma.